|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PIGG |
Gene summary for PIGG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PIGG | Gene ID | 54872 |
| Gene name | phosphatidylinositol glycan anchor biosynthesis class G | |
| Gene Alias | GPI7 | |
| Cytomap | 4p16.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q5H8A4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54872 | PIGG | LZE7T | Human | Esophagus | ESCC | 3.40e-02 | 1.45e-01 | 0.0667 |
| 54872 | PIGG | LZE8T | Human | Esophagus | ESCC | 3.69e-02 | 2.36e-02 | 0.067 |
| 54872 | PIGG | LZE20T | Human | Esophagus | ESCC | 1.49e-05 | 1.54e-01 | 0.0662 |
| 54872 | PIGG | LZE22T | Human | Esophagus | ESCC | 1.08e-03 | 1.66e-01 | 0.068 |
| 54872 | PIGG | LZE24T | Human | Esophagus | ESCC | 3.23e-12 | 2.25e-01 | 0.0596 |
| 54872 | PIGG | P1T-E | Human | Esophagus | ESCC | 1.21e-05 | 2.96e-01 | 0.0875 |
| 54872 | PIGG | P2T-E | Human | Esophagus | ESCC | 1.45e-20 | 3.35e-01 | 0.1177 |
| 54872 | PIGG | P4T-E | Human | Esophagus | ESCC | 3.22e-09 | 1.81e-01 | 0.1323 |
| 54872 | PIGG | P5T-E | Human | Esophagus | ESCC | 4.56e-05 | 1.76e-02 | 0.1327 |
| 54872 | PIGG | P8T-E | Human | Esophagus | ESCC | 1.67e-18 | 3.24e-01 | 0.0889 |
| 54872 | PIGG | P9T-E | Human | Esophagus | ESCC | 4.68e-09 | 7.64e-02 | 0.1131 |
| 54872 | PIGG | P10T-E | Human | Esophagus | ESCC | 8.28e-14 | 1.13e-01 | 0.116 |
| 54872 | PIGG | P11T-E | Human | Esophagus | ESCC | 4.28e-05 | 1.66e-01 | 0.1426 |
| 54872 | PIGG | P12T-E | Human | Esophagus | ESCC | 1.40e-13 | 1.81e-01 | 0.1122 |
| 54872 | PIGG | P15T-E | Human | Esophagus | ESCC | 5.70e-11 | 1.77e-01 | 0.1149 |
| 54872 | PIGG | P16T-E | Human | Esophagus | ESCC | 2.81e-14 | 2.22e-01 | 0.1153 |
| 54872 | PIGG | P17T-E | Human | Esophagus | ESCC | 6.30e-08 | 2.58e-01 | 0.1278 |
| 54872 | PIGG | P20T-E | Human | Esophagus | ESCC | 4.20e-07 | 1.34e-01 | 0.1124 |
| 54872 | PIGG | P21T-E | Human | Esophagus | ESCC | 2.44e-06 | 1.49e-01 | 0.1617 |
| 54872 | PIGG | P22T-E | Human | Esophagus | ESCC | 9.02e-04 | 8.34e-02 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
| GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
| GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
| GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
| GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
| GO:00464673 | Esophagus | ESCC | membrane lipid biosynthetic process | 91/8552 | 142/18723 | 7.19e-06 | 7.19e-05 | 91 |
| GO:00421573 | Esophagus | ESCC | lipoprotein metabolic process | 86/8552 | 135/18723 | 1.78e-05 | 1.57e-04 | 86 |
| GO:00064973 | Esophagus | ESCC | protein lipidation | 62/8552 | 92/18723 | 2.08e-05 | 1.80e-04 | 62 |
| GO:00421583 | Esophagus | ESCC | lipoprotein biosynthetic process | 64/8552 | 96/18723 | 2.61e-05 | 2.20e-04 | 64 |
| GO:00065063 | Esophagus | ESCC | GPI anchor biosynthetic process | 26/8552 | 32/18723 | 3.97e-05 | 3.21e-04 | 26 |
| GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
| GO:00065053 | Esophagus | ESCC | GPI anchor metabolic process | 26/8552 | 33/18723 | 1.06e-04 | 7.43e-04 | 26 |
| GO:00066642 | Esophagus | ESCC | glycolipid metabolic process | 63/8552 | 100/18723 | 3.55e-04 | 2.06e-03 | 63 |
| GO:19035092 | Esophagus | ESCC | liposaccharide metabolic process | 63/8552 | 101/18723 | 5.25e-04 | 2.90e-03 | 63 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:0009247 | Esophagus | ESCC | glycolipid biosynthetic process | 42/8552 | 68/18723 | 5.48e-03 | 2.05e-02 | 42 |
| GO:00066611 | Esophagus | ESCC | phosphatidylinositol biosynthetic process | 73/8552 | 131/18723 | 1.31e-02 | 4.28e-02 | 73 |
| GO:00086542 | Liver | HCC | phospholipid biosynthetic process | 150/7958 | 253/18723 | 4.77e-08 | 1.03e-06 | 150 |
| GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
| GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005632 | Esophagus | ESCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 21/4205 | 26/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 21 |
| hsa0056311 | Esophagus | ESCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 21/4205 | 26/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 21 |
| hsa00563 | Liver | HCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 18/4020 | 26/8465 | 2.08e-02 | 4.81e-02 | 2.68e-02 | 18 |
| hsa005631 | Liver | HCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 18/4020 | 26/8465 | 2.08e-02 | 4.81e-02 | 2.68e-02 | 18 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PIGG | SNV | Missense_Mutation | novel | c.1728G>C | p.Gln576His | p.Q576H | Q5H8A4 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| PIGG | SNV | Missense_Mutation | rs782615666 | c.762G>C | p.Glu254Asp | p.E254D | Q5H8A4 | protein_coding | tolerated(0.47) | benign(0.058) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| PIGG | SNV | Missense_Mutation | c.815N>T | p.Ser272Phe | p.S272F | Q5H8A4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PIGG | SNV | Missense_Mutation | c.1918N>T | p.Pro640Ser | p.P640S | Q5H8A4 | protein_coding | tolerated(0.51) | benign(0.003) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| PIGG | SNV | Missense_Mutation | c.2429G>A | p.Arg810Lys | p.R810K | Q5H8A4 | protein_coding | tolerated(0.08) | probably_damaging(0.994) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PIGG | deletion | Frame_Shift_Del | novel | c.1196_1209delNNNNNNNNNNNNNN | p.Glu399AlafsTer59 | p.E399Afs*59 | Q5H8A4 | protein_coding | TCGA-AQ-A54N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| PIGG | deletion | Frame_Shift_Del | novel | c.2178delN | p.Leu728CysfsTer65 | p.L728Cfs*65 | Q5H8A4 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| PIGG | SNV | Missense_Mutation | rs755547556 | c.1490C>T | p.Ser497Leu | p.S497L | Q5H8A4 | protein_coding | tolerated(0.3) | benign(0.015) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PIGG | SNV | Missense_Mutation | novel | c.2356N>C | p.Asp786His | p.D786H | Q5H8A4 | protein_coding | deleterious(0.01) | possibly_damaging(0.713) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| PIGG | SNV | Missense_Mutation | novel | c.369G>A | p.Met123Ile | p.M123I | Q5H8A4 | protein_coding | tolerated(0.05) | benign(0.022) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |